Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | DRD3 | P35462 | 3/20 | 0.40 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.40 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | GPR183 | P32249 | 1/20 | 0.39 |
| ▸ | ADGRF1 | Q5T601 | 1/20 | 0.39 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.39 |
| ▸ | TSPO | P30536 | 1/20 | 0.38 |
| ▸ | RNF4 | P78317 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3819010 | 0.80 | RNF4 (0.47) | CNR2CNR1DRD2DRD3BCL2A1 | |
| SCHEMBL3058445 | 0.78 | SCN4A (0.38) | CNR2CNR1NR1H4CHRM2CHRM1 | |
| SCHEMBL3819221 | 0.77 | CHRM2 (0.44) | CNR2CNR1DRD2DRD3BCL2A1 | |
| SCHEMBL8170417 | 0.76 | CNR2 (0.55) | CNR2CNR1 | |
| SCHEMBL15173714 | 0.74 | SMN1; SMN2 (0.49) | — | |
| SCHEMBL27594337 | 0.73 | CNR1 (0.41) | CNR2CNR1DRD2DRD3 | |
| SCHEMBL3824522 | 0.73 | CHRM1 (0.47) | CNR2CNR1DRD2DRD3CHRM2 | |
| SCHEMBL3819014 | 0.72 | CNR2 (0.46) | CNR2CNR1DRD2DRD3 | |
| SCHEMBL4735333 | 0.72 | ALDH1A1 (0.48) | DRD2DRD3CHRM2CHRM1CHRM3 | |
| SCHEMBL4736992 | 0.72 | MEN1 (0.43) | DRD2DRD3BCL2A1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267697-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2010-10-21 | — | — | US | claimed |
| EP-2099754-A1 | ION CHANNEL MODULATORS | Wyeth a Corporation of the State of Delaware (US) | 2009-09-16 | — | — | EP | claimed |
| WO-2008073929-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | claimed |
| US-20100267697-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267697-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267697-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267697-A1 | ION CHANNEL MODULATORS | CACNA1E, CACNA1A, CACNA1S | CNR2 262/4885CNR1 221/4885DRD2 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.